Team

Patrick Van Beneden (1962) has worked at Gimv since 1985 and joined the Executive Committee in February 2001. He heads up the Life Sciences business unit. 

He is a board member of various listed and non-listed investments, including Acertys, ActoGeniX, Astex, DeVGen, Pamgene, TorreyPines Therapeutics and the Biotech Fonds Vlaanderen. Former board seats include Innogenetics, Crucell, Avalon, Hypnion (acquired by Eli Lilly) and Crop Design (acquired by BASF).

Patrick Van Beneden has a degree in Financial Sciences from VLEKHO in Brussels.

Jim Van heusden (1971) currently serves on the board of ActoGeniX (Belgium), Pronota (Belgium) and Prosensa (The Netherlands) and has been a board member at CropDesign (acquired by BASF). 

Prior to joining Gimv in 2001, he worked as a senior scientist at the department of Oncology Drug Discovery at Janssen Pharmaceutica, a Johnson & Johnson company, where he also served on the research management committee of the collaboration with Rigel Pharmaceuticals (US).

He holds BSc and MSc degrees in chemistry and biochemistry from the University of Antwerp (Belgium) and a PhD in molecular and cellular biology from the University of Maastricht (The Netherlands).

Christophe Van Vaeck (1973) started at Gimv in 2008 as a Senior Investment Manager. 

During the previous eight years, he had been working as a Financial Analyst in the Life Sciences sector. He started his career at Bank Degroof and later worked at KBC Securities, where he guided several IPOs, including those of Galapagos, deVGen, Thrombogenics and Ablynx.

Christophe Van Vaeck earned his PhD in Biology at the lab of Molecular and Cellular Biology at Katholieke Universiteit Leuven (Belgium).